CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

19-537 / S-048, S-050, S-051
20-780 / S-012, S-014, S-015

Trade Name: CIPRO

Generic Name: Ciprofloxacin Tablets
              Ciprofloxacin Oral Suspension

Sponsor: Bayer Corporation Pharmaceutical Division

Approval Date: March 15, 2004
APPLICATION NUMBER:

19-537 / S-048, S-050, S-051
20-780 / S-012, S-014, S-015

CONTENTS

**Reviews / Information Included in this NDA Review.**

<table>
<thead>
<tr>
<th>Approval Letter</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approvable Letter</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology/ Biopharmaceutics Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td></td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:

19-537 / S-048, S-050, S-051
20-780 / S-012, S-014, S-015

APPROVAL LETTER
DEPARTMENT OF HEALTH & HUMAN SERVICES

NDA 19-537/S-048, S-050, S-051
NDA 20-780/S-012, S-014, S-015

Bayer Corporation Pharmaceutical Division
Attention: Andrew S. Verderame
Director, Regulatory Affairs
400 Morgan Lane
West Haven, CT 06516-4175

Dear Mr. Verderame:

Please refer to your supplemental new drug applications, which were submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

<table>
<thead>
<tr>
<th>NDA #</th>
<th>Drug Product</th>
<th>Supplement Number</th>
<th>Letter Date</th>
<th>Receipt Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>19-537</td>
<td>Cipro® (ciprofloxacin hydrochloride) Tablets, 100 mg, 250 mg, 500 mg, 750mg</td>
<td>S-048</td>
<td>September 11, 2003</td>
<td>September 15, 2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S-050</td>
<td>January 26, 2004</td>
<td>January 27, 2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S-051</td>
<td>January 26, 2004</td>
<td>January 28, 2004</td>
</tr>
<tr>
<td>20-780</td>
<td>Cipro® (ciprofloxacin) Oral Suspension, 5% and 10%</td>
<td>S-012</td>
<td>September 11, 2003</td>
<td>September 15, 2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S-014</td>
<td>January 26, 2004</td>
<td>January 27, 2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S-015</td>
<td>January 26, 2004</td>
<td>January 28, 2004</td>
</tr>
</tbody>
</table>

We acknowledge receipt of your submission dated November 7, 2003 for NDA 19-537/S-048, and your submissions dated February 25, 2004 for NDA 19-537/S-048, S-050, S-051, and NDA 20-780/S-012, S-014, S-015.

NDA 19-537/S-048 (tablets) and NDA 20-780/S-012 (oral solution) were submitted as Changes Being Effected (CBE) and provide for additional safety information in the label. Revisions are included in the WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE sections of the package insert.
NDA 19-537/SL-050 (tablets) and NDA 20-780/SLR-014 (oral solution) were submitted as Changes Being Effect #ed (CBE) and provide for antibacterial drug resistance labeling revisions as specified in the Division’s September 11, 2003 letter. This CBE request letter was sent per the Final Rule entitled “Labeling Requirements for Systemic Antibacterial Drug Products Intended for Human Use “(68FR 6062, February 6, 2003).

NDA 19-537/SL-051 (tablets) and NDA 20-780/ SLR-015 (oral solution) were submitted as Changes Being Effect #d (CBE) and provide for additional safety information in the label. Revisions are included in the WARNINGS, and ADVERSE REACTIONS sections of the package insert.

These supplements provide for the following changes to the Cipro® Tablet and Oral Suspension label. Deleted text is noted by strike-through and added text is noted by double underline:

**NDA 19-537/S-048 (tablets) and NDA 20-780/S-012 (oral solution):**

1. The following sentence was added to the WARNINGS section:

   Achilles and other tendon ruptures that required surgical repair or resulted in prolonged disability have been reported with ciprofloxacin and other quinolones. Post-marketing surveillance reports indicate that the risk may be increased in patients receiving concomitant corticosteroids, especially in the elderly. Ciprofloxacin should be discontinued if the patient experiences pain, inflammation, or rupture of a tendon.

2. The PRECAUTIONS, Drug Interactions subsection was revised as follows:

   Quinolones, including ciprofloxacin, have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives. When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be closely monitored.

   Probencid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in the serum. This should be considered if patients are receiving both drugs concomitantly.

   Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin potentially leading to increased plasma levels of methotrexate. This might increase the risk of methotrexate associated toxic reactions. Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.

   Metoclopramide accelerates the absorption of oral ciprofloxacin resulting in shorter time to reach maximum plasma concentrations. No effect was seen on the bioavailability of ciprofloxacin.

   Animal studies have shown that the combination of very high doses of quinolones and certain non-steroidal anti-inflammatory agents (but not acetylsalicylic acid) can provoke convulsions.
3. The **ADVERSE REACTIONS** section was revised as follows:

**BODY AS A WHOLE:** headache, abdominal pain/discomfort, foot pain, pain, pain in extremities, injection site reaction (ciprofloxacin intravenous)

**CARDIOVASCULAR:** palpitation, atrial flutter, ventricular ectopy, syncope, hypertension, angina pectoris, myocardial infarction, cardiopulmonary arrest, cerebral thrombosis, phlebitis, tachycardia, migraine, hypotension

**CENTRAL NERVOUS SYSTEM:** restlessness, dizziness, lightheadedness, insomnia, nightmares, hallucinations, manic reaction, irritability, tremor, ataxia, convulsive seizures, lethargy, drowsiness, weakness, malaise, anorexia, phobia, depersonalization, depression, paresthesia, abnormal gait, grand mal convulsion (See above.) (See **PRECAUTIONS**.)

**GASTROINTESTINAL:** painful oral mucosa, oral candidiasis, dysphagia, intestinal perforation, gastrointestinal bleeding (See above.) Cholestatic/bleeding, cholestatic jaundice, hepatitis jaundice has been reported.

**HEMIC/LYMPHATIC:** lymphadenopathy, petechia

**METABOLIC/NUTRITIONAL:** amylase increase, lipase increase

**MUSCULOSKELETAL:** arthralgia or back pain, joint stiffness, achiness, neck or chest pain, flare up of gout

**RENA/LUROGENITAL:** interstitial nephritis, nephritis, renal failure, polyuria, urinary retention, urethral bleeding, vaginitis, acidosis, breast pain

**RESPIRATORY:** dyspnea, epistaxis, laryngeal or pulmonary edema, hiccough, hemoptyis, bronchospasm, pulmonary embolism

**SKIN/HYPERSENSITIVITY:** pruritus, urticaria, photosensitivity, flushing, fever, chills, angioedema, edema of the face, neck, lips, conjunctivae or hands, cutaneous candidiasis, hyperpigmentation, erythema, nodosum, sweating

Allergic reactions ranging from urticaria to anaphylactic reactions have been reported. (See **WARNINGS**.)

**SPECIAL SENSES:** blurred vision, disturbed vision (change in color perception, overbrightness of lights), decreased visual acuity, diplopia, eye pain, tinnitus, hearing loss, bad taste, chromatopsia

**Post-Marketing Adverse Events:** Additional adverse events, regardless of relationship to drug. The following adverse events have been reported from worldwide marketing experience with quinolones, including ciprofloxacin are: ciprofloxacin. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these events in labeling are typically based on one or more of the following factors: (1) seriousness of the event, (2) frequency of the reporting, or (3) strength of causal connection to the drug.

Agitation, agranulocytosis, albuminuria, anaphylactic reactions, anosmia, candiduria, cholesterol elevation (serum), confusion, constipation, delirium, dyspepsia, dysphagia,
erythema multiforme, exfoliative dermatitis, fixed eruption, flatulence, glucose elevation (blood), hemolytic anemia, hepatic failure, hepatic necrosis, hyperesthesia, hypertonia, hypesthesia, hypotension (postural), jaundice, marrow depression (life threatening), methemoglobinemia, monoliasis (oral, gastrointestinal, vaginal) myalgia, myasthenia, myasthenia gravis (possible exacerbation), myoclonus, nystagmus, pancreatitis, pancytopenia (life threatening or fatal outcome), phenytoin alteration (serum), potassium elevation (serum), prothrombin time prolongation or decrease, pseudomembranous colitis (The onset of pseudomembranous colitis symptoms may occur during or after antimicrobial treatment.), psychosis (toxic), renal calculi, serum sickness like reaction, Stevens-Johnson syndrome, taste loss, tendinitis, tendon rupture, toxic epidermal necrolysis, triglyceride elevation (serum), twitching, vaginal candidiasis, and vasculitis. (See PRECAUTIONS.)

4. The OVERDOSAGE section was revised as follows:

In the event of acute overdosage, reversible renal toxicity has been reported in some cases. The stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be carefully observed and given supportive treatment, including monitoring of renal function and administration of magnesium or calcium containing antacids which can treatment. reduce the absorption of ciprofloxacin. Adequate hydration must be maintained. Only a small amount of ciprofloxacin (< 10%) is removed from the body after hemodialysis or peritoneal dialysis.

Single doses of ciprofloxacin were relatively non-toxic via the oral route of administration in mice, rats, and dogs. No deaths occurred within a 14-day post treatment observation period at the highest oral doses tested; up to 5000 mg/kg in either rodent species, or up to 2500 mg/kg in the dog. Clinical signs observed included hypoactivity and cyanosis in both rodent species and severe vomiting in dogs. In rabbits, significant mortality was seen at doses of ciprofloxacin > 2500 mg/kg. Mortality was delayed in these animals, occurring 10-14 days after dosing.

In mice, rats, rabbits and dogs, significant toxicity including tonic/clonic convulsions was observed at intravenous doses of ciprofloxacin between 125 and 300 mg/kg.

NDA 19-537/SLR-050 (tablets) and NDA 20-780/SLR-014 (oral solution):

1. The following sentence was added at the beginning of the label under the Product Name:

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRO Tablets and CIPRO Oral Suspension and other antibacterial drugs, CIPRO Tablets and CIPRO Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
2. The following was added as the last paragraph in the **INDICATIONS AND USAGE** section:

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRO Tablets and CIPRO Oral Suspension and other antibacterial drugs, CIPRO Tablets and CIPRO Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

3. The following was added as the last paragraph in the **PRECAUTIONS** section, **General:** subsection:

Prescribing CIPRO Tablets and CIPRO Oral Suspension in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

4. The following was added as the first bullet in the **PRECAUTIONS** section, **Information for Patients:** subsection:

- that antibacterial drugs including CIPRO Tablets and CIPRO Oral Suspension should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When CIPRO Tablets and CIPRO Oral Suspension is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by CIPRO Tablets and CIPRO Oral Suspension or other antibacterial drugs in the future.

**NDA 19-537/SLR-051 (tablets) and NDA 20-780/SLR-015 (oral solution):**

1. The following sentence was added to the eighth paragraph of the **WARNINGS** section:

After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against *C. difficile* colitis. Drugs that inhibit peristalsis should be avoided.
2. The **ADVERSE REACTIONS** section was revised as follows:

   SKIN/HYPERSENSITIVITY: allergic reaction, pruritus, urticaria, photosensitivity, flushing, fever, chills, angioedema, edema of the face, neck, lips, conjunctivae or hands, cutaneous candidiasis, hyperpigmentation, erythema nodosum, sweating

We completed our review of these applications and they are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed draft labeling (text for the package insert submitted February 25, 2004).

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "**FPL for approved supplements NDA 19-537/S-048, S-050, S-051 and NDA 20-780/S-012, S-014, S-015**.” Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about these drug products (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to each NDA and a copy to the following address:

   **MEDWATCH, HFD-410**
   FDA
   5600 Fishers Lane
   Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Christine Lincoln, Labeling Reviewer, at (301) 827-2127.

   Sincerely,

   {See appended electronic signature page}

   Renata Albrecht, M.D.
   Director
   Division of Special Pathogen and Immunologic Drug Products
   Office of Drug Evaluation IV
   Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

------------------------
Renata Albrecht
3/15/04 05:25:38 PM
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

19-537 / S-048, S-050, S-051
20-780 / S-012, S-014, S-015

LABELING
CIPRO® (ciprofloxacin hydrochloride) TABLETS
CIPRO® (ciprofloxacin*) ORAL SUSPENSION

DESCRIPTION

CIPRO® (ciprofloxacin hydrochloride) Tablets and CIPRO (ciprofloxacin) Oral Suspension are synthetic broad spectrum antimicrobial agents for oral administration. Ciprofloxacin hydrochloride, USP, is a fluoroquinolone, is the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. It is a faintly yellowish to light yellow crystalline substance with a molecular weight of 385.8. Its empirical formula is C₁₇H₁₈FN₃O₅·HCl·H₂O and its chemical structure is as follows:

![Chemical structure of Ciprofloxacin](image)

Ciprofloxacin is 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. Its empirical formula is C₁₇H₁₈FN₃O₅ and its molecular weight is 331.4. It is a faintly yellowish to light yellow crystalline substance and its chemical structure is as follows:

![Chemical structure of Ciprofloxacin](image)

CIPRO film-coated tablets are available in 100 mg, 250 mg, 500 mg and 750 mg (ciprofloxacin equivalent) strengths. Ciprofloxacin tablets are white to slightly yellowish. The inactive ingredients are cornstarch, microcrystalline cellulose, silicon dioxide, crospovidone, magnesium stearate, hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol and water.

Ciprofloxacin Oral Suspension is available in 5% (5 g ciprofloxacin in 100 mL) and 10% (10 g ciprofloxacin in 100 mL) strengths. Ciprofloxacin Oral Suspension is a white to slightly yellowish suspension with strawberry flavor which may contain yellow-orange droplets. It is composed of ciprofloxacin microcapsules and diluent which are mixed prior to dispensing (See instructions for USE/HANDLING). The components of the suspension have the following compositions:

- Microcapsules - ciprofloxacin, polyvinylpyrrolidone, methacrylic acid copolymer, hydroxypropyl methylcellulose, magnesium stearate, and Polysorbate 20.
- Diluent - medium-chain triglycerides, sucrose, lecithin, water, and strawberry flavor.

* Does not comply with USP with regards to "loss on drying" and "residue on ignition".
CLINICAL PHARMACOLOGY

Absorption: Ciprofloxacin given as an oral tablet is rapidly and well absorbed from the gastrointestinal tract after oral administration. The absolute bioavailability is approximately 70% with no substantial loss by first pass metabolism. Ciprofloxacin maximum serum concentrations and area under the curve are shown in the chart for the 250 mg to 1000 mg dose range.

<table>
<thead>
<tr>
<th>Dose (mg)</th>
<th>Maximum Serum Concentration (µg/mL)</th>
<th>Area Under Curve (AUC) (µg·hr/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>250</td>
<td>1.2</td>
<td>4.8</td>
</tr>
<tr>
<td>500</td>
<td>2.4</td>
<td>11.6</td>
</tr>
<tr>
<td>750</td>
<td>4.3</td>
<td>20.2</td>
</tr>
<tr>
<td>1000</td>
<td>5.4</td>
<td>30.8</td>
</tr>
</tbody>
</table>

Maximum serum concentrations are attained 1 to 2 hours after oral dosing. Mean concentrations 12 hours after dosing with 250, 500, or 750 mg are 0.1, 0.2, and 0.4 mg/mL, respectively. The serum elimination half-life in subjects with normal renal function is approximately 4 hours. Serum concentrations increase proportionately with doses up to 1000 mg.

A 500 mg oral dose given every 12 hours has been shown to produce an area under the serum concentration time curve (AUC) equivalent to that produced by an intravenous infusion of 400 mg ciprofloxacin given over 60 minutes every 12 hours. A 750 mg oral dose given every 12 hours has been shown to produce an AUC at steady-state equivalent to that produced by an intravenous infusion of 400 mg given over 60 minutes every 8 hours. A 750 mg oral dose results in a Cmax similar to that observed with a 400 mg I.V. dose. A 250 mg oral dose given every 12 hours produces an AUC equivalent to that produced by an infusion of 200 mg ciprofloxacin given every 12 hours.

### Steady-state Pharmacokinetic Parameters Following Multiple Oral and I.V. Doses

<table>
<thead>
<tr>
<th>Parameters</th>
<th>500 mg</th>
<th>400 mg</th>
<th>750 mg</th>
<th>400 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>q12h, P.O.</td>
<td>q12h, I.V.</td>
<td>q12h, P.O.</td>
<td>q8h, I.V.</td>
<td></td>
</tr>
<tr>
<td>AUC (µg·hr/mL)</td>
<td>13.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>12.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>31.6&lt;sup&gt;b&lt;/sup&gt;</td>
<td>32.9&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Cmax (µg/mL)</td>
<td>2.97</td>
<td>4.56</td>
<td>3.59</td>
<td>4.07</td>
</tr>
</tbody>
</table>

<sup>a</sup>AUC 0-12h<sup>b</sup>AUC 24h=AUC0-12hx2<sup>c</sup>AUC 24h=AUC0-8hx3

Distribution: The binding of ciprofloxacin to serum proteins is 20 to 40% which is not likely to be high enough to cause significant protein binding interactions with other drugs.

After oral administration, ciprofloxacin is widely distributed throughout the body. Tissue concentrations often exceed serum concentrations in both men and women, particularly in genital tissue including the prostate. Ciprofloxacin is present in active form in the saliva, nasal and bronchial secretions, mucosa of the sinuses, sputum, skin blister fluid, lymph, peritoneal fluid, bile, and prostatic secretions. Ciprofloxacin has also been detected in lung, skin, fat, muscle, cartilage, and bone. The drug diffuses into the cerebrospinal fluid (CSF); however,
CSF concentrations are generally less than 10% of peak serum concentrations. Low levels of the drug have been detected in the aqueous and vitreous humors of the eye.

**Metabolism:** Four metabolites have been identified in human urine which together account for approximately 15% of an oral dose. The metabolites have antimicrobial activity, but are less active than unchanged ciprofloxacin.

**Excretion:** The serum elimination half-life in subjects with normal renal function is approximately 4 hours. Approximately 40 to 50% of an orally administered dose is excreted in the urine as unchanged drug. After a 250-mg oral dose, urine concentrations of ciprofloxacin usually exceed 200 µg/mL during the first two hours and are approximately 30 µg/mL at 8 to 12 hours after dosing. The urinary excretion of ciprofloxacin is virtually complete within 24 hours after dosing. The renal clearance of ciprofloxacin, which is approximately 300 mL/minute, exceeds the normal glomerular filtration rate of 120 mL/minute. Thus, active tubular secretion would seem to play a significant role in its elimination. Co-administration of probenecid with ciprofloxacin results in about a 50% reduction in the ciprofloxacin renal clearance and a 50% increase in its concentration in the systemic circulation. Although bile concentrations of ciprofloxacin are several fold higher than serum concentrations after oral dosing, only a small amount of the dose administered is recovered from the bile as unchanged drug. An additional 1 to 2% of the dose is recovered from the bile in the form of metabolites. Approximately 20 to 35% of an oral dose is recovered from the feces within 5 days after dosing. This may arise from either biliary clearance or transintestinal elimination.

With oral administration, a 500 mg dose, given as 10 mL of the 5% CIPRO Suspension (containing 250 mg ciprofloxacin/5mL) is bioequivalent to the 500 mg tablet. A 10 mL volume of the 5% CIPRO Suspension (containing 250 mg ciprofloxacin/5mL) is bioequivalent to a 5 mL volume of the 10% CIPRO Suspension (containing 500 mg ciprofloxacin/5mL).

**Drug-drug Interactions:** When CIPRO Tablet is given concomitantly with food, there is a delay in the absorption of the drug, resulting in peak concentrations that occur closer to 2 hours after dosing rather than 1 hour whereas there is no delay observed when CIPRO Suspension is given with food. The overall absorption of CIPRO Tablet or CIPRO Suspension, however, is not substantially affected. The pharmacokinetics of ciprofloxacin given as the suspension are also not affected by food. Concurrent administration of antacids containing magnesium hydroxide or aluminum hydroxide may reduce the bioavailability of ciprofloxacin by as much as 90%. (See PRECAUTIONS.)

The serum concentrations of ciprofloxacin and metronidazole were not altered when these two drugs were given concomitantly.

Concomitant administration of ciprofloxacin with theophylline decreases the clearance of theophylline resulting in elevated serum theophylline levels and increased risk of a patient development CNS or other adverse reactions. Ciprofloxacin also decreases caffeine clearance and inhibits the formation of paraxanthine after caffeine administration. (See PRECAUTIONS.)

**Special Populations:** Pharmacokinetic studies of the oral (single dose) and intravenous (single and multiple dose) forms of ciprofloxacin indicate that plasma concentrations of ciprofloxacin are higher in elderly subjects (>65 years) as compared to young adults. Although the Cmax is increased 16-40%, the increase in mean AUC is approximately 30%, and can be at least partially attributed to decreased renal clearance in the elderly. Elimination half-life is only
slightly (~20%) prolonged in the elderly. These differences are not considered clinically significant. (See PRECAUTIONS: Geriatric Use.)

In patients with reduced renal function, the half-life of ciprofloxacin is slightly prolonged. Dosage adjustments may be required. (See DOSAGE AND ADMINISTRATION.)

In preliminary studies in patients with stable chronic liver cirrhosis, no significant changes in ciprofloxacin pharmacokinetics have been observed. The kinetics of ciprofloxacin in patients with acute hepatic insufficiency, however, have not been fully elucidated.

**Microbiology:** Ciprofloxacin has *in vitro* activity against a wide range of gram-negative and gram-positive microorganisms. The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. The mechanism of action of fluoroquinolones, including ciprofloxacin, is different from that of penicillins, cephalosporins, aminoglycosides, macrolides, and tetracyclines; therefore, microorganisms resistant to these classes of drugs may be susceptible to ciprofloxacin and other quinolones. There is no known cross-resistance between ciprofloxacin and other classes of antimicrobials. *In vitro* resistance to ciprofloxacin develops slowly by multiple step mutations.

Ciprofloxacin is slightly less active when tested at acidic pH. The inoculum size has little effect when tested *in vitro*. The minimal bactericidal concentration (MBC) generally does not exceed the minimal inhibitory concentration (MIC) by more than a factor of 2.

Ciprofloxacin has been shown to be active against most strains of the following microorganisms, both *in vitro* and in clinical infections as described in the **INDICATIONS AND USAGE** section of the package insert for CIPRO (ciprofloxacin hydrochloride) Tablets and CIPRO (ciprofloxacin) 5% and 10% Oral Suspension.

**Aerobic gram-positive microorganisms**
- *Enterococcus faecalis* (Many strains are only moderately susceptible.)
- *Staphylococcus aureus* (methicillin-susceptible strains only)
- *Staphylococcus epidermidis* (methicillin-susceptible strains only)
- *Staphylococcus saprophyticus*
- *Streptococcus pneumoniae* (penicillin-susceptible strains only)
- *Streptococcus pyogenes*
Aerobic gram-negative microorganisms

- Campylobacter jejuni
- Proteus mirabilis
- Citrobacter diversus
- Proteus vulgaris
- Citrobacter freundii
- Providencia rettgeri
- Enterobacter cloacae
- Providencia stuartii
- Escherichia coli
- Pseudomonas aeruginosa
- Haemophilus influenzae
- Salmonella typhi
- Haemophilus parainfluenzae
- Serratia marcescens
- Klebsiella pneumoniae
- Shigella boydii
- Moraxella catarrhalis
- Shigella dysenteriae
- Morganella morganii
- Shigella flexneri
- Neisseria gonorrhoeae
- Shigella sonnei

Ciprofloxacin has been shown to be active against *Bacillus anthracis* both in vitro and by use of serum levels as a surrogate marker (see **INDICATIONS AND USAGE** and **INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION**).

The following in vitro data are available, **but their clinical significance is unknown**.

Ciprofloxacin exhibits in vitro minimum inhibitory concentrations (MICs) of 1 µg/mL or less against most (≥90%) strains of the following microorganisms; however, the safety and effectiveness of ciprofloxacin in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.

Aerobic gram-positive microorganisms

- Staphylococcus haemolyticus
- Staphylococcus hominis
- Streptococcus pneumoniae (penicillin-resistant strains only)

Aerobic gram-negative microorganisms

- Acinetobacter Iwoffii
- Pasteurella multocida
- Aeromonas hydrophila
- Salmonella enteritidis
- Edwardsiella tarda
- Vibrio cholerae
- Enterobacter aerogenes
- Vibrio parahaemolyticus
- Klebsiella oxytoca
- Vibrio vulnificus
- Legionella pneumophila
- Yersinia enterocolitica

Most strains of *Burkholderia cepacia* and some strains of *Stenotrophomonas maltophilia* are resistant to ciprofloxacin as are most anaerobic bacteria, including *Bacteroides fragilis* and *Clostridium difficile*.

**Susceptibility Tests**

**Dilution Techniques:** Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of ciprofloxacin powder. The MIC values should be interpreted according to the following criteria:
For testing aerobic microorganisms other than *Haemophilus influenzae*, *Haemophilus parainfluenzae*, and *Neisseria gonorrhoeae*:

<table>
<thead>
<tr>
<th>MIC (μg/mL)</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 1</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td>2</td>
<td>Intermediate (I)</td>
</tr>
<tr>
<td>≥ 4</td>
<td>Resistant (R)</td>
</tr>
</tbody>
</table>

*a* These interpretive standards are applicable only to broth microdilution susceptibility tests with streptococci using cation-adjusted Mueller-Hinton broth with 2-5% lysed horse blood.

For testing *Haemophilus influenzae* and *Haemophilus parainfluenzae*:

<table>
<thead>
<tr>
<th>MIC (μg/mL)</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 1</td>
<td>Susceptible (S)</td>
</tr>
</tbody>
</table>

*b* This interpretive standard is applicable only to broth microdilution susceptibility tests with *Haemophilus influenzae* and *Haemophilus parainfluenzae* using *Haemophilus* Test Medium.¹

The current absence of data on resistant strains precludes defining any results other than “Susceptible”. Strains yielding MIC results suggestive of a “nonsusceptible” category should be submitted to a reference laboratory for further testing.

For testing *Neisseria gonorrhoeae*:

<table>
<thead>
<tr>
<th>MIC (μg/mL)</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 0.06</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td>0.12 – 0.5</td>
<td>Intermediate (I)</td>
</tr>
<tr>
<td>≥ 1</td>
<td>Resistant (R)</td>
</tr>
</tbody>
</table>

*c* This interpretive standard is applicable only to agar dilution test with GC agar base and 1% defined growth supplement.

A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of “Intermediate” indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone, which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.
Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard ciprofloxacin powder should provide the following MIC values:

<table>
<thead>
<tr>
<th>Organism</th>
<th>MIC (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>E. faecalis</em></td>
<td>ATCC 29212</td>
</tr>
<tr>
<td><em>E. coli</em></td>
<td>ATCC 25922</td>
</tr>
<tr>
<td><em>H. influenzae</em></td>
<td>ATCC 49247</td>
</tr>
<tr>
<td><em>N. gonorrhoeae</em></td>
<td>ATCC 49226</td>
</tr>
<tr>
<td><em>P. aeruginosa</em></td>
<td>ATCC 27853</td>
</tr>
<tr>
<td><em>S. aureus</em></td>
<td>ATCC 29213</td>
</tr>
</tbody>
</table>

*a* This quality control range is applicable to only *H. influenzae* ATCC 49247 tested by a broth microdilution procedure using *Haemophilus* Test Medium (HTM).¹

*b* This quality control range is applicable to only *N. gonorrhoeae* ATCC 49226 tested by an agar dilution procedure using GC agar base and 1% defined growth supplement.

**Diffusion Techniques:** Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure² requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 5-µg ciprofloxacin to test the susceptibility of microorganisms to ciprofloxacin.

Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5-µg ciprofloxacin disk should be interpreted according to the following criteria:

For testing aerobic microorganisms other than *Haemophilus influenzae*, *Haemophilus parainfluenzae*, and *Neisseria gonorrhoeae*:²

<table>
<thead>
<tr>
<th>Zone Diameter (mm)</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥21</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td>16-20</td>
<td>Intermediate (I)</td>
</tr>
<tr>
<td>≤15</td>
<td>Resistant (R)</td>
</tr>
</tbody>
</table>

*a* These zone diameter standards are applicable only to tests performed for streptococci using Mueller-Hinton agar supplemented with 5% sheep blood incubated in 5% CO₂.

For testing *Haemophilus influenzae* and *Haemophilus parainfluenzae*:²

<table>
<thead>
<tr>
<th>Zone Diameter (mm)</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥21</td>
<td>Susceptible (S)</td>
</tr>
</tbody>
</table>

*b* This zone diameter standard is applicable only to tests with *Haemophilus influenzae* and *Haemophilus parainfluenzae* using *Haemophilus* Test Medium (HTM).²
The current absence of data on resistant strains precludes defining any results other than "Susceptible." Strains yielding zone diameter results suggestive of a "nonsusceptible" category should be submitted to a reference laboratory for further testing.

For testing *Neisseria gonorrhoeae*:

<table>
<thead>
<tr>
<th>Zone Diameter (mm)</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 41</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td>28 – 40</td>
<td>Intermediate (I)</td>
</tr>
<tr>
<td>≤ 27</td>
<td>Resistant (R)</td>
</tr>
</tbody>
</table>

This zone diameter standard is applicable only to disk diffusion tests with GC agar base and 1% defined growth supplement.

Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for ciprofloxacin.

As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 5-μg ciprofloxacin disk should provide the following zone diameters in these laboratory test quality control strains:

<table>
<thead>
<tr>
<th>Organism</th>
<th>Zone Diameter (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>E. coli</em></td>
<td>ATCC 25922</td>
</tr>
<tr>
<td><em>H. influenzae</em></td>
<td>ATCC 49247</td>
</tr>
<tr>
<td><em>N. gonorrhoeae</em></td>
<td>ATCC 49226</td>
</tr>
<tr>
<td><em>P. aeruginosa</em></td>
<td>ATCC 27853</td>
</tr>
<tr>
<td><em>S. aureus</em></td>
<td>ATCC 25923</td>
</tr>
</tbody>
</table>

\[a\] These quality control limits are applicable to only *H. influenzae* ATCC 49247 testing using *Haemophilus* Test Medium (HTM).\[b\]

\[b\] These quality control limits are applicable only to tests conducted with *N. gonorrhoeae* ATCC 49226 performed by disk diffusion using GC agar base and 1% defined growth supplement.

**INDICATIONS AND USAGE**

CIPRO is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations.

**Urinary Tract Infections** caused by *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter cloacae*, *Serratia marcescens*, *Proteus mirabilis*, *Providencia rettgeri*, *Morganella morganii*, *Citrobacter diversus*, *Citrobacter freundii*, *Pseudomonas aeruginosa*, *Staphylococcus epidermidis*, *Staphylococcus saprophyticus*, or *Enterococcus faecalis*.

**Acute Uncomplicated Cystitis in females** caused by *Escherichia coli* or *Staphylococcus saprophyticus*. (See DOSAGE AND ADMINISTRATION.)
Chronic Bacterial Prostatitis caused by *Escherichia coli* or *Proteus mirabilis*.


NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to *Streptococcus pneumoniae*.

Acute Sinusitis caused by *Haemophilus influenzae*, *Streptococcus pneumoniae*, or *Moraxella catarrhalis*.

Skin and Skin Structure Infections caused by *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter cloacae*, *Proteus mirabilis*, *Proteus vulgaris*, *Providencia stuartii*, *Morganella morganii*, *Citrobacter freundii*, *Pseudomonas aeruginosa*, *Staphylococcus aureus* (meticillin-susceptible), *Staphylococcus epidermidis*, or *Streptococcus pyogenes*.

Bone and Joint Infections caused by *Enterobacter cloacae*, *Serratia marcescens*, or *Pseudomonas aeruginosa*.

Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by *Escherichia coli*, *Pseudomonas aeruginosa*, *Proteus mirabilis*, *Klebsiella pneumoniae*, or *Bacteroides fragilis*. (See DOSAGE AND ADMINISTRATION.)

Infectious Diarrhea caused by *Escherichia coli* (enterotoxigenic strains), *Campylobacter jejuni*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri* or *Shigella sonnei* when antibacterial therapy is indicated.

Typhoid Fever (Enteric Fever) caused by *Salmonella typhi*.

NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated.

Uncomplicated cervical and urethral gonorrhea due to *Neisseria gonorrhoeae*.

Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.

Ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication.* (See also, INHALATIONAL ANTHRAX – ADDITIONAL INFORMATION).

*Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients.

If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with CIPRO may be initiated before results of these
tests are known; once results become available appropriate therapy should be continued. As
with other drugs, some strains of *Pseudomonas aeruginosa* may develop resistance fairly
rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed
periodically during therapy will provide information not only on the therapeutic effect of the
antimicrobial agent but also on the possible emergence of bacterial resistance.

**CONTRAINDICATIONS**

CIPRO (ciprofloxacin hydrochloride) is contraindicated in persons with a history of
hypersensitivity to ciprofloxacin or any member of the quinolone class of antimicrobial agents.

**WARNINGS**

**THE SAFETY AND EFFECTIVENESS OF CIPROFLOXACIN IN PEDIATRIC PATIENTS AND
ADOLESCENTS (LESS THAN 18 YEARS OF AGE).** - EXCEPT FOR USE IN INHALATIONAL
**ANTHRAX (POST-EXPOSURE), PREGNANT WOMEN, AND LACTATING WOMEN HAVE
NOT BEEN ESTABLISHED.** (See PRECAUTIONS: Pediatric Use, Pregnancy, and Nursing
**Mothers** subsections.) The oral administration of ciprofloxacin caused lameness in immature
dogs. Histopathological examination of the weight-bearing joints of these dogs revealed
permanent lesions of the cartilage. Related quinolone-class drugs also produce erosions of
cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various
species. (See ANIMAL PHARMACOLOGY.)

Convulsions, increased intracranial pressure, and toxic psychosis have been reported in
patients receiving quinolones, including ciprofloxacin. Ciprofloxacin may also cause central
nervous system (CNS) events including: dizziness, confusion, tremors, hallucinations,
 depression, and, rarely, suicidal thoughts or acts. These reactions may occur following the first
dose. If these reactions occur in patients receiving ciprofloxacin, the drug should be
discontinued and appropriate measures instituted. As with all quinolones, ciprofloxacin should
be used with caution in patients with known or suspected CNS disorders that may predispose to
seizures or lower the seizure threshold (e.g. severe cerebral arteriosclerosis, epilepsy), or in the
presence of other risk factors that may predispose to seizures or lower the seizure threshold
(e.g. certain drug therapy, renal dysfunction). (See PRECAUTIONS: General, Information for
Patients, Drug Interactions and ADVERSE REACTIONS.)

**SERIOUS AND FATAL REACTIONS HAVE BEEN REPORTED IN PATIENTS RECEIVING
CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AND THEOPHYLLINE.** These
reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure.
Although similar serious adverse effects have been reported in patients receiving theophylline
alone, the possibility that these reactions may be potentiated by ciprofloxacin cannot be
eliminated. If concomitant use cannot be avoided, serum levels of theophylline should be
monitored and dosage adjustments made as appropriate.

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first
dose, have been reported in patients receiving quinolone therapy. Some reactions were
accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial
edema, dyspnea, urticaria, and itching. Only a few patients had a history of hypersensitivity
reactions. Serious anaphylactic reactions require immediate emergency treatment with
epinephrine. Oxygen, intravenous steroids, and airway management, including intubation,
should be administered as indicated.
Severe hypersensitivity reactions characterized by rash, fever, eosinophilia, jaundice, and hepatic necrosis with fatal outcome have also been rarely reported in patients receiving ciprofloxacin along with other drugs. The possibility that these reactions were related to ciprofloxacin cannot be excluded. Ciprofloxacin should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity.

Pseudomembranous colitis has been reported with nearly all antibacterial agents, including ciprofloxacin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by *Clostridium difficile* is one primary cause of "antibiotic-associated colitis."

After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against *C. difficile* colitis.

Achilles and other tendon ruptures that required surgical repair or resulted in prolonged disability have been reported with ciprofloxacin and other quinolones. Ciprofloxacin should be discontinued if the patient experiences pain, inflammation, or rupture of a tendon.

Ciprofloxacin has not been shown to be effective in the treatment of syphilis. Antimicrobial agents used in high dose for short periods of time to treat gonorrhea may mask or delay the symptoms of incubating syphilis. All patients with gonorrhea should have a serologic test for syphilis at the time of diagnosis. Patients treated with ciprofloxacin should have a follow-up serologic test for syphilis after three months.

**PRECAUTIONS**

**General:** Crystals of ciprofloxacin have been observed rarely in the urine of human subjects but more frequently in the urine of laboratory animals, which is usually alkaline. (See **ANIMAL PHARMACOLOGY.**) Crystalluria related to ciprofloxacin has been reported only rarely in humans because human urine is usually acidic. Alkalinity of the urine should be avoided in patients receiving ciprofloxacin. Patients should be well hydrated to prevent the formation of highly concentrated urine.

Quinolones, including ciprofloxacin, may also cause central nervous system (CNS) events, including: nervousness, agitation, insomnia, anxiety, nightmares or paranoia. (See **WARNINGS, Information for Patients, and Drug Interactions.**)

Alteration of the dosage regimen is necessary for patients with impairment of renal function. (See **DOSEAGE AND ADMINISTRATION.**)

Moderate to severe phototoxicity manifested as an exaggerated sunburn reaction has been observed in patients who are exposed to direct sunlight while receiving some members of the quinolone class of drugs. Excessive sunlight should be avoided. Therapy should be discontinued if phototoxicity occurs.
As with any potent drug, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic function, is advisable during prolonged therapy.

**Information for Patients:**

Patients should be advised:

- that ciprofloxacin may be taken with or without meals and to drink fluids liberally. As with other quinolones, concurrent administration of ciprofloxacin with magnesium/aluminum antacids, or sucralfate, Videx® (didanosine) chewable/buffered tablets or pediatric powder, or with other products containing calcium, iron or zinc should be avoided. Ciprofloxacin may be taken two hours before or six hours after taking these products. Ciprofloxacin should not be taken with dairy products (like milk or yogurt) or calcium-fortified juices alone since absorption of ciprofloxacin may be significantly reduced; however, ciprofloxacin may be taken with a meal that contains these products.

- that ciprofloxacin may be associated with hypersensitivity reactions, even following a single dose, and to discontinue the drug at the first sign of a skin rash or other allergic reaction.

- to avoid excessive sunlight or artificial ultraviolet light while receiving ciprofloxacin and to discontinue therapy if phototoxicity occurs.

- to discontinue treatment; rest and refrain from exercise; and inform their physician if they experience pain, inflammation, or rupture of a tendon.

- that ciprofloxacin may cause dizziness and lightheadedness; therefore, patients should know how they react to this drug before they operate an automobile or machinery or engage in activities requiring mental alertness or coordination.

- that ciprofloxacin may increase the effects of theophylline and caffeine. There is a possibility of caffeine accumulation when products containing caffeine are consumed while taking quinolones.

- that convulsions have been reported in patients receiving quinolones, including ciprofloxacin, and to notify their physician before taking this drug if there is a history of this condition.

**Drug Interactions:** As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life. This may result in increased risk of theophylline-related adverse reactions. (See **WARNINGs**.) If concomitant use cannot be avoided, serum levels of theophylline should be monitored and dosage adjustments made as appropriate.

Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine. This may lead to reduced clearance of caffeine and a prolongation of its serum half-life.

Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium/aluminum antacids, sucralfate, Videx® (didanosine) chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease its absorption, resulting in serum and urine levels considerably lower.
than desired. (See DOSAGE AND ADMINISTRATION for concurrent administration of these
agents with ciprofloxacin.)

Histamine H₂-receptor antagonists appear to have no significant effect on the bioavailability of
ciprofloxacin.

Altered serum levels of phenytoin (increased and decreased) have been reported in patients
receiving concomitant ciprofloxacin.

The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare
occasions, resulted in severe hypoglycemia.

Some quinolones, including ciprofloxacin, have been associated with transient elevations in
serum creatinine in patients receiving cyclosporine concomitantly.

Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its
derivatives. When these products are administered concomitantly, prothrombin time or other
suitable coagulation tests should be closely monitored.

Probenecid interferes with renal tubular secretion of ciprofloxacin and produces
an increase in the level of ciprofloxacin in the serum. This should be considered
if patients are receiving both drugs concomitantly.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Eight in vitro mutagenicity tests have
been conducted with ciprofloxacin, and the test results are listed below:

Salmonella/Microsome Test (Negative)
E. coli DNA Repair Assay (Negative)
Mouse Lymphoma Cell Forward Mutation Assay (Positive)
Chinese Hamster V₇₉ Cell HGPRT Test (Negative)
Syrian Hamster Embryo Cell Transformation Assay (Negative)
Saccharomyces cerevisiae Point Mutation Assay (Negative)
Saccharomyces cerevisiae Mitotic Crossover and Gene Conversion
Assay (Negative)
Rat Hepatocyte DNA Repair Assay (Positive)

Thus, 2 of the 8 tests were positive, but results of the following 3 in vivo test systems gave
negative results:

Rat Hepatocyte DNA Repair Assay
Micronucleus Test (Mice)
Dominant Lethal Test (Mice)

Long-term carcinogenicity studies in mice and rats have been completed. After daily oral doses
of 750 mg/kg (mice) and 250 mg/kg (rats) were administered for up to 2 years, there was no
evidence that ciprofloxacin had any carcinogenic or tumorigenic effects in these species.

Results from photo co-carcinogenicity testing indicate that ciprofloxacin does not reduce the
time to appearance of UV-induced skin tumors as compared to vehicle control. Hairless (Skh-1)
mice were exposed to UVA light for 3.5 hours five times every two weeks for up to 78 weeks
while concurrently being administered ciprofloxacin. The time to development of the first skin
tumors was 50 weeks in mice treated concomitantly with UVA and ciprofloxacin (mouse dose
approximately equal to maximum recommended human dose based upon mg/m²), as opposed
to 34 weeks when animals were treated with both UVA and vehicle. The times to development
of skin tumors ranged from 16-32 weeks in mice treated concomitantly with UVA and other
quinolones.³

In this model, mice treated with ciprofloxacin alone did not develop skin or systemic tumors.
There are no data from similar models using pigmented mice and/or fully haired mice. The
clinical significance of these findings to humans is unknown.

Fertility studies performed in rats at oral doses of ciprofloxacin up to 100 mg/kg (0.8 times the
highest recommended human dose of 1200 mg based upon body surface area) revealed no
evidence of impairment.

Pregnancy: Teratogenic Effects. Pregnancy Category C:

There are no adequate and well-controlled studies in pregnant women. An expert review of
published data on experiences with ciprofloxacin use during pregnancy by TERIS – the
Teratogen Information System - concluded that therapeutic doses during pregnancy are
unlikely to pose a substantial teratogenic risk (quantity and quality of data=fair), but the data are
insufficient to state that there is no risk.⁴

A controlled prospective observational study followed 200 women exposed to fluoroquinolones-
(52.5% exposed to ciprofloxacin and 68% first trimester exposures) during gestation.⁵ In utero
exposure to fluoroquinolones during embryogenesis was not associated with increased risk of
major malformations. The reported rates of major congenital malformations were 2.2% for the
fluoroquinolone group and 2.6% for the control group (background incidence of major
malformations is 1-5%). Rates of spontaneous abortions, prematurity and low birth weight did
not differ between the groups and there were no clinically significant musculoskeletal
dysfunctions up to one year of age in the ciprofloxacin exposed children.

Another prospective follow-up study reported on 549 pregnancies with fluoroquinolone
exposure (93% first trimester exposures).⁶ There were 70 ciprofloxacin exposures, all within the
first trimester. The malformation rates among live-born babies exposed to ciprofloxacin and to
fluoroquinolones overall were both within background incidence ranges. No specific patterns of
congenital abnormalities were found. The study did not reveal any clear adverse reactions due
to in utero exposure to ciprofloxacin.

No differences in the rates of prematurity, spontaneous abortions, or birth weight were seen in
women exposed to ciprofloxacin during pregnancy.⁷,⁸ However, these small postmarketing
epidemiology studies, of which most experience is from short term, first trimester exposure, are
insufficient to evaluate the risk for less common defects or to permit reliable and definitive
conclusions regarding the safety of ciprofloxacin in pregnant women and their developing
fetuses. Ciprofloxacin should not be used during pregnancy unless the potential benefit
justifies the potential risk to both fetus and mother (see WARNINGS).

Reproduction studies have been performed in rats and mice using oral doses up to 100 mg/kg
(0.6 and 0.3 times the maximum daily human dose based upon body surface area, respectively)
and have revealed no evidence of harm to the fetus due to ciprofloxacin. In rabbits,
ciprofloxacin (30 and 100 mg/kg orally) produced gastrointestinal disturbances resulting in
maternal weight loss and an increased incidence of abortion, but no teratogenicity was
observed at either dose. After intravenous administration of doses up to 20 mg/kg, no maternal
toxicity was produced in the rabbit, and no embryotoxicity or teratogenicity was observed. (See
WARNINGS.)

Nursing Mothers: Ciprofloxacin is excreted in human milk. The amount of ciprofloxacin
absorbed by the nursing infant is unknown. Because of the potential for serious adverse
reactions in infants nursing from mothers taking ciprofloxacin, a decision should be made
whether to discontinue nursing or to discontinue the drug, taking into account the importance of
the drug to the mother.

Pediatric Use: Safety and effectiveness in pediatric patients and adolescents less than 18
years of age have not been established, except for use in inhalational anthrax (post-exposure).
Ciprofloxacin causes arthropathy in juvenile animals. (See WARNINGS.)

For the indication of inhalational anthrax (post-exposure), the risk-benefit assessment indicates
that administration of ciprofloxacin to pediatric patients is appropriate. For information
regarding pediatric dosing in inhalational anthrax (post-exposure), see DOSAGE AND
ADMINISTRATION and INHALATIONAL ANTHRAX — ADDITIONAL INFORMATION.

Short-term safety data from a single trial in pediatric cystic fibrosis patients are available. In a
randomized, double-blind clinical trial for the treatment of acute pulmonary exacerbations in
cystic fibrosis patients (ages 5-17 years), 67 patients received ciprofloxacin I.V. 10 mg/kg/dose
q8h for one week followed by ciprofloxacin tablets 20 mg/kg/dose q12h to complete 10-21 days
treatment and 62 patients received the combination of ceftazidime I.V. 50 mg/kg/dose q8h and
tobramycin I.V. 3 mg/kg/dose q8h for a total of 10-21 days. Patients less than 5 years of age
were not studied. Safety monitoring in the study included periodic range of motion examinations
and gait assessments by treatment-blinded examiners. Patients were followed for an average of
23 days after completing treatment (range 0-93 days). This study was not designed to
determine long term effects and the safety of repeated exposure to ciprofloxacin.

In the study, injection site reactions were more common in the ciprofloxacin group (24%) than in
the comparison group (8%). Other adverse events were similar in nature and frequency
between treatment arms. Musculoskeletal adverse events were reported in 22% of the patients
in the ciprofloxacin group and 21% in the comparison group. Decreased range of motion was
reported in 12% of the subjects in the ciprofloxacin group and 16% in the comparison group.
Arthralgia was reported in 10% of the patients in the ciprofloxacin group and 11% in the
comparison group. One of sixty-seven patients developed arthritis of the knee nine days after a
ten day course of treatment with ciprofloxacin. Clinical symptoms resolved, but an MRI showed
knee effusion without other abnormalities eight months after treatment. However, the
relationship of this event to the patient’s course of ciprofloxacin can not be definitively
determined, particularly since patients with cystic fibrosis may develop arthralgias/arthritis as
part of their underlying disease process.

Geriatric Use: In a retrospective analysis of 23 multiple-dose controlled clinical trials of
ciprofloxacin encompassing over 3500 ciprofloxacin treated patients, 25% of patients were
greater than or equal to 65 years of age and 10% were greater than or equal to 75 years of
age. No overall differences in safety or effectiveness were observed between these subjects
and younger subjects, and other reported clinical experience has not identified differences in
responses between the elderly and younger patients, but greater sensitivity of some older
individuals on any drug therapy cannot be ruled out. Ciprofloxacin is known to be substantially
excreted by the kidney, and the risk of adverse reactions may be greater in patients with
impair renal function. No alteration of dosage is necessary for patients greater than 65 years
of age with normal renal function. However, since some older individuals experience reduced
renal function by virtue of their advanced age, care should be taken in dose selection for elderly
patients, and renal function monitoring may be useful in these patients. (See CLINICAL
PHARMACOLOGY and DOSAGE AND ADMINISTRATION.)

ADVERSE REACTIONS
During clinical investigation with the tablet, 2,799 patients received 2,868 courses of the drug.
Most of the adverse events reported were described as only mild or moderate in severity,
abated soon after the drug was discontinued, and required no treatment. Ciprofloxacin was
discontinued because of an adverse event in 3.5% of patients treated.

The most frequently reported events, drug related or not, were nausea (5.2%), diarrhea (2.3%),
vomiting (2.0%), abdominal pain/discomfort (1.7%), headache (1.2%), restlessness (1.1%), and
rash (1.1%).

Additional events that occurred in less than 1% of ciprofloxacin patients are listed below.

BODY AS A WHOLE: foot pain
CARDIOVASCULAR: palpitation, atrial flutter, ventricular ectopy, syncope, hypertension,
angina pectoris, myocardial infarction, cardiopulmonary arrest, cerebral thrombosis
CENTRAL NERVOUS SYSTEM: dizziness, lightheadedness, insomnia,
nightmares, hallucinations, manic reaction, irritability, tremor, ataxia, convulsive
seizures, lethargy, drowsiness, weakness, malaise, anorexia, phobia,
depersonalization, depression, paresthesia (See above.) (See
PRECAUTIONS.)
GASTROINTESTINAL: painful oral mucosa, oral candidiasis, dysphagia,
intestinal perforation, gastrointestinal bleeding (See above.) Cholestatic
jaundice has been reported.
HEMICY/LYMPHATIC: lymphadenopathy
MUSCULOSKELETAL: arthralgia or back pain, joint stiffness, achiness, neck or
chest pain, flare up of gout
RENAL/URETHERAL: interstitial nephritis, nephritis, renal failure, polyuria,
urinary retention, urethral bleeding, vaginitis, acidosis, breast pain
RESPIRATORY: dyspnea, epistaxis, laryngeal or pulmonary edema, hiccough,
hemoptysis, bronchospasm, pulmonary embolism
SKIN/HYPERSENSITIVITY: pruritus, urticaria, photosensitivity, flushing, fever,
chills, angioedema, edema of the face, neck, lips, conjunctivae or hands,
cutaneous candidiasis, hyperpigmentation, erythema nodosum (See above.)
Allergic reactions ranging from urticaria to anaphylactic reactions have been
reported. (See WARNINGS.)
SPECIAL SENSES: blurred vision, disturbed vision (change in color
perception, overbrightness of lights), decreased visual acuity, diplopia, eye
pain, tinnitus, hearing loss, bad taste
In several instances nausea, vomiting, tremor, irritability, or palpitation were judged by investigators to be related to elevated serum levels of theophylline possibly as a result of drug interaction with ciprofloxacin.

In randomized, double-blind controlled clinical trials comparing ciprofloxacin tablets (500 mg BID) to cefuroxime axetil (250 mg - 500 mg BID) and to clarithromycin (500 mg BID) in patients with respiratory tract infections, ciprofloxacin demonstrated a CNS adverse event profile comparable to the control drugs.

Post-Marketing Adverse Events: Additional adverse events, regardless of relationship to drug, reported from worldwide marketing experience with quinolones, including ciprofloxacin, are:

agitation, agranulocytosis, albuminuria, anaphylactic reactions, anosmia, candiduria, cholesterol elevation (serum), confusion, constipation, delirium, dyspepsia, dysphagia, erythema multiforme, exfoliative dermatitis, flatulence, glucose elevation (blood), hemolytic anemia, hepatic necrosis, hypotension (postural), jaundice, methemoglobinemia, myalgia, myasthenia gravis (possible exacerbation), myoclonus, nystagmus, pancreatitis, phenytoin alteration (serum), potassium elevation (serum), prothrombin time prolongation, pseudomembranous colitis (The onset of pseudomembranous colitis symptoms may occur during or after antimicrobial treatment.), psychosis (toxic), renal calculi, Stevens-Johnson syndrome, taste loss, tendinitis, tendon rupture, toxic epidermal necrolysis, triglyceride elevation (serum), vaginal candidiasis, and vasculitis (See PRECAUTIONS.)

Adverse Laboratory Changes: Changes in laboratory parameters listed as adverse events without regard to drug relationship are listed below:

Hepatic - Elevations of ALT (SGPT) (1.9%), AST (SGOT) (1.7%), alkaline phosphatase (0.8%), LDH (0.4%), serum bilirubin (0.3%).

Hematologic - Eosinophilia (0.6%), leukopenia (0.4%), decreased blood platelets (0.1%), elevated blood platelets (0.1%), pancytopenia (0.1%).

Renal - Elevations of serum creatinine (1.1%), BUN (0.9%), CRYSTALLURIA, CYLINDRURIA, AND HEMATURIA HAVE BEEN REPORTED.

Other changes occurring in less than 0.1% of courses were: elevation of serum gammaglutamyl transferase, elevation of serum amylase, reduction in blood glucose, elevated uric acid, decrease in hemoglobin, anemia, bleeding diathesis, increase in blood monocytes, leukocytosis.

OVERDOSE

In the event of acute overdosage, the stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be carefully observed and given supportive treatment. Adequate hydration must be maintained. Only a small amount of ciprofloxacin (<10%) is removed from the body after hemodialysis or peritoneal dialysis.

Single doses of ciprofloxacin were relatively non-toxic via the oral route of administration in mice, rats, and dogs. No deaths occurred within a 14-day post treatment observation period at the highest oral doses tested; up to 5000 mg/kg in either rodent species, or up to 2500 mg/kg in
the dog. Clinical signs observed included hypoactivity and cyanosis in both rodent species and severe vomiting in dogs. In rabbits, significant mortality was seen at doses of ciprofloxacin > 2500 mg/kg. Mortality was delayed in these animals, occurring 10-14 days after dosing.

In mice, rats, rabbits and dogs, significant toxicity including tonic/clonic convulsions was observed at intravenous doses of ciprofloxacin between 125 and 300 mg/kg.

**DOSAGE AND ADMINISTRATION**

CIPRO Tablets and Oral Suspension should be administered orally as described in the Dosage Guidelines table.

The determination of dosage for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative organism, the integrity of the patient's host-defense mechanisms, and the status of renal function and hepatic function.

The duration of treatment depends upon the severity of infection. The usual duration is 7 to 14 days; however, for severe and complicated infections more prolonged therapy may be required. Ciprofloxacin should be administered at least 2 hours before or 6 hours after magnesium/aluminum antacids, or sucralfate, Videx® (didanosine) chewable / buffered tablets or pediatric powder for oral solution, or other products containing calcium, iron or zinc.
<table>
<thead>
<tr>
<th>Infection</th>
<th>Type or Severity</th>
<th>Unit Dose</th>
<th>Frequency</th>
<th>Usual Durations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urinary Tract</td>
<td>Acute Uncomplicated</td>
<td>100 mg or 250 mg</td>
<td>q 12 h</td>
<td>3 Days</td>
</tr>
<tr>
<td></td>
<td>Mild/Moderate</td>
<td>250 mg</td>
<td>q 12 h</td>
<td>7 to 14 Days</td>
</tr>
<tr>
<td></td>
<td>Severe/Complicated</td>
<td>500 mg</td>
<td>q 12 h</td>
<td>7 to 14 Days</td>
</tr>
<tr>
<td>Chronic Bacterial Prostatitis</td>
<td>Mild/Moderate</td>
<td>500 mg</td>
<td>q 12 h</td>
<td>28 Days</td>
</tr>
<tr>
<td>Lower Respiratory Tract</td>
<td>Mild/Moderate</td>
<td>500 mg</td>
<td>q 12 h</td>
<td>7 to 14 days</td>
</tr>
<tr>
<td></td>
<td>Severe/Complicated</td>
<td>750 mg</td>
<td>q 12 h</td>
<td>7 to 14 days</td>
</tr>
<tr>
<td>Acute Sinusitis</td>
<td>Mild/Moderate</td>
<td>500 mg</td>
<td>q 12 h</td>
<td>10 days</td>
</tr>
<tr>
<td>Skin and Skin Structure</td>
<td>Mild/Moderate</td>
<td>500 mg</td>
<td>q 12 h</td>
<td>7 to 14 Days</td>
</tr>
<tr>
<td></td>
<td>Severe/Complicated</td>
<td>750 mg</td>
<td>q 12 h</td>
<td>7 to 14 Days</td>
</tr>
<tr>
<td>Bone and Joint</td>
<td>Mild/Moderate</td>
<td>500 mg</td>
<td>q 12 h</td>
<td>≥ 4 to 6 weeks</td>
</tr>
<tr>
<td></td>
<td>Severe/Complicated</td>
<td>750 mg</td>
<td>q 12 h</td>
<td>≥ 4 to 6 weeks</td>
</tr>
<tr>
<td>Intra-Abdominal*</td>
<td>Complicated</td>
<td>500 mg</td>
<td>q 12 h</td>
<td>7 to 14 Days</td>
</tr>
<tr>
<td>Infectious Diarrhea</td>
<td>Mild/Moderate/Severe</td>
<td>500 mg</td>
<td>q 12 h</td>
<td>5 to 7 Days</td>
</tr>
<tr>
<td>Typhoid Fever</td>
<td>Mild/Moderate</td>
<td>500 mg</td>
<td>q 12 h</td>
<td>10 Days</td>
</tr>
<tr>
<td>Urethral and Cervical</td>
<td>Uncomplicated</td>
<td>250 mg</td>
<td>single dose</td>
<td>single dose</td>
</tr>
<tr>
<td>Gonococcal Infections</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhalational anthrax</td>
<td>Adult</td>
<td>500 mg</td>
<td>q 12 h</td>
<td>60 Days</td>
</tr>
<tr>
<td>(post-exposure)</td>
<td>Pediatric</td>
<td>15 mg/kg per dose, not to exceed 500 mg per dose</td>
<td>q 12 h</td>
<td>60 Days</td>
</tr>
</tbody>
</table>

* used in conjunction with metronidazole
† Generally ciprofloxacin should be continued for at least 2 days after the signs and symptoms of infection have disappeared, except for inhalational anthrax (post-exposure).
** Drug administration should begin as soon as possible after suspected or confirmed exposure.
This indication is based on a surrogate endpoint, ciprofloxacin serum concentrations achieved in humans, reasonably likely to predict clinical benefit. For a discussion of ciprofloxacin serum concentrations in various human populations, see INHALATIONAL ANTHRAX – ADDITIONAL INFORMATION.

832 Patients whose therapy is started with CIPRO I.V. may be switched to CIPRO Tablets or Oral Suspension when clinically indicated at the discretion of the physician (See CLINICAL PHARMACOLOGY and table below for the equivalent dosing regimens).

### Equivalent AUC Dosing Regimens

<table>
<thead>
<tr>
<th>Cipro Oral Dosage</th>
<th>Equivalent Cipro I.V Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 mg Tablet q 12 h</td>
<td>200 mg I.V. q 12 h</td>
</tr>
<tr>
<td>500 mg Tablet q 12 h</td>
<td>400 mg I.V. q 12 h</td>
</tr>
<tr>
<td>750 mg Tablet q 12 h</td>
<td>400 mg I.V. q 8 h</td>
</tr>
</tbody>
</table>

837 **Impaired Renal Function:** Ciprofloxacin is eliminated primarily by renal excretion; however, the drug is also metabolized and partially cleared through the biliary system of the liver and through the intestine. These alternative pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment. Nonetheless, some modification of dosage is recommended, particularly for patients with severe renal dysfunction. The following
RECOMMENDED STARTING AND MAINTENANCE DOSES
FOR PATIENTS WITH IMPAIRED RENAL FUNCTION

<table>
<thead>
<tr>
<th>Creatinine Clearance (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;50</td>
<td>See Usual Dosage.</td>
</tr>
<tr>
<td>30 - 50</td>
<td>250-500 mg q 12 h</td>
</tr>
<tr>
<td>5 - 29</td>
<td>250-500 mg q 18 h</td>
</tr>
<tr>
<td>Patients on hemodialysis</td>
<td>250-500 mg q 24 h (after dialysis)</td>
</tr>
<tr>
<td>or Peritoneal dialysis</td>
<td></td>
</tr>
</tbody>
</table>

When only the serum creatinine concentration is known, the following formula may be used to estimate creatinine clearance.

Men: Creatinine clearance (mL/min) = \( \frac{\text{Weight (kg)} \times (140-\text{age})}{72 \times \text{serum creatinine (mg/dL)}} \)

Women: 0.85 x the value calculated for men.

The serum creatinine should represent a steady state of renal function.

In patients with severe infections and severe renal impairment, a unit dose of 750 mg may be administered at the intervals noted above; however, patients should be carefully monitored and the serum ciprofloxacin concentration should be measured periodically. Peak concentrations (1-2 hours after dosing) should generally range from 2 to 4 µg/mL.

For patients with changing renal function or for patients with renal impairment and hepatic insufficiency, measurement of serum concentrations of ciprofloxacin will provide additional guidance for adjusting dosage.

HOW SUPPLIED

CIPRO (ciprofloxacin hydrochloride) Tablets are available as round, slightly yellowish film-coated tablets containing 100 mg or 250 mg ciprofloxacin. The 100 mg tablet is coded with the word “CIPRO” on one side and “100” on the reverse side. The 250 mg tablet is coded with the word “CIPRO” on one side and “250” on the reverse side. CIPRO is also available as capsule shaped, slightly yellowish film-coated tablets containing 500-mg or 750 mg ciprofloxacin. The 500 mg tablet is coded with the word “CIPRO” on one side and “500” on the reverse side. The 750 mg tablet is coded with the word “CIPRO” on one side and “750” on the reverse side.

CIPRO 250 mg, 500 mg, and 750 mg are available in bottles of 50, 100, and Unit Dose packages of 100. The 100 mg strength is available only as CIPRO Cystitis pack containing 6 tablets for use only in female patients with acute uncomplicated cystitis.
<table>
<thead>
<tr>
<th>Strength</th>
<th>NDC Code</th>
<th>Tablet Identification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bottles of 50:</td>
<td>750 mg</td>
<td>CIPRO 750</td>
</tr>
<tr>
<td>Bottles of 100:250 mg</td>
<td>NDC 0026-8512-51</td>
<td>CIPRO 250</td>
</tr>
<tr>
<td>500 mg</td>
<td>NDC 0026-8513-51</td>
<td>CIPRO 500</td>
</tr>
<tr>
<td>Unit Dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Package of 100:</td>
<td>250 mg</td>
<td>CIPRO 250</td>
</tr>
<tr>
<td>500 mg</td>
<td>NDC 0026-8513-48</td>
<td>CIPRO 500</td>
</tr>
<tr>
<td>750 mg</td>
<td>NDC 0026-8514-48</td>
<td>CIPRO 750</td>
</tr>
<tr>
<td>Cystitis</td>
<td>Package of 6:</td>
<td></td>
</tr>
<tr>
<td>100 mg</td>
<td>NDC 0026-8511-06</td>
<td>CIPRO 100</td>
</tr>
</tbody>
</table>

Store below 30°C (86°F).

CIPRO Oral Suspension is supplied in 5% and 10% strengths. The drug product is composed of two components (microcapsules containing the active ingredient and diluent) which must be mixed by the pharmacist. See Instructions To The Pharmacist For Use/Handling.

<table>
<thead>
<tr>
<th>Strengths</th>
<th>Total volume after reconstitution</th>
<th>Ciprofloxacin Concentration</th>
<th>Ciprofloxacin contents per bottle</th>
<th>NDC Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>5%</td>
<td>100 mL</td>
<td>250 mg/5 mL</td>
<td>5,000 mg</td>
<td>0026-8551-36</td>
</tr>
<tr>
<td>10%</td>
<td>100 mL</td>
<td>500 mg/5 mL</td>
<td>10,000 mg</td>
<td>0026-8553-36</td>
</tr>
</tbody>
</table>

Microcapsules and diluent should be stored below 25°C (77°F) and protected from freezing.

Reconstituted product may be stored below 30°C (86°F) for 14 days. Protect from freezing. A teaspoon is provided for the patient.

ANIMAL PHARMACOLOGY

Ciprofloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species tested. (See WARNINGS.) Damage of weight bearing joints was observed in juvenile dogs and rats. In young beagles, 100 mg/kg ciprofloxacin, given daily for 4 weeks, caused degenerative articular changes of the knee joint. At 30 mg/kg, the effect on the joint was minimal. In a subsequent study in beagles, removal of weight bearing from the joint reduced the lesions but did not totally prevent them.

Crystalluria, sometimes associated with secondary nephropathy, occurs in laboratory animals dosed with ciprofloxacin. This is primarily related to the reduced solubility of ciprofloxacin under alkaline conditions, which predominate in the urine of test animals; in man, crystalluria is rare since human urine is typically acidic. In rhesus monkeys, crystalluria without nephropathy has been noted after single oral doses as low as 5 mg/kg. After 6 months of intravenous dosing at 10 mg/kg/day, no nephropathological changes were noted; however, nephropathy was observed after dosing at 20 mg/kg/day for the same duration.
In dogs, ciprofloxacin at 3 and 10 mg/kg by rapid IV injection (15 sec.) produces pronounced hypotensive effects. These effects are considered to be related to histamine release, since they are partially antagonized by pyrilamine, an antihistamine. In rhesus monkeys, rapid IV injection also produces hypotension but the effect in this species is inconsistent and less pronounced.

In mice, concomitant administration of nonsteroidal anti-inflammatory drugs such as phenylbutazone and indomethacin with quinolones has been reported to enhance the CNS stimulatory effect of quinolones.

Ocular toxicity seen with some related drugs has not been observed in ciprofloxacin-treated animals.

CLINICAL STUDIES

Uncomplicated Cystitis

Two double-blind, controlled clinical studies of acute uncomplicated cystitis in women were performed in the U.S. At the 5-9 day post-therapy follow-up visit, the clinical resolution rates in the first study, which compared ciprofloxacin 100 mg BID for 3 days to ciprofloxacin 250 mg BID for 7 days, were 87% (82/94) and 94%, (81/86), respectively. For E. coli, the bacteriological eradication rates for the first study were 91% (64/70) in the ciprofloxacin 100 mg regimen and 97% (67/69) in the ciprofloxacin 250 mg regimen. The second study's bacteriological eradication rates were 95% (117/123) for the ciprofloxacin 100 mg regimen and 98% (103/105) for the control regimen. Pooled eradication rates for the ciprofloxacin 100 mg treatment arms were 100% (16/16) for S. saprophyticus.

INHALATIONAL ANTHRAX – ADDITIONAL INFORMATION

The mean serum concentrations of ciprofloxacin associated with a statistically significant improvement in survival in the rhesus monkey model of inhalational anthrax are reached or exceeded in adult and pediatric patients receiving oral and intravenous regimens. (See DOSAGE AND ADMINISTRATION.) Ciprofloxacin pharmacokinetics have been evaluated in various human populations. The mean peak serum concentration achieved at steady state in human adults receiving 500 mg orally every 12 hours is 2.97 μg/ml, and 4.56 μg/ml following 400 mg intravenously every 12 hours. The mean trough serum concentration at steady-state for both of these regimens is 0.2 μg/ml. In a study of 10 pediatric patients between 6 and 16 years of age, the mean peak plasma concentration achieved is 8.3 μg/mL and trough concentrations range from 0.09 to 0.26 μg/mL, following two 30-minute intravenous infusions of 10 mg/kg administered 12 hours apart. After the second intravenous infusion patients switched to 15 mg/kg orally every 12 hours achieve a mean peak concentration of 3.6 μg/mL after the initial oral dose. Long-term safety data, including effects on cartilage, following the administration of ciprofloxacin to pediatric patients are limited. (For additional information, see PRECAUTIONS, Pediatric Use.) Ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication.4

A placebo-controlled animal study in rhesus monkeys exposed to an inhaled mean dose of 11 LD_{50} (~5.5 \times 10^6) spores (range 5-30 LD_{50}) of B. anthracis was conducted. The minimal inhibitory concentration (MIC) of ciprofloxacin for the anthrax strain used in this study was 0.08 μg/ml. In the animals studied, mean serum concentrations of ciprofloxacin achieved at expected T\textsubscript{max} (1 hour post-dose) following oral dosing to steady state ranged from 0.98 to 1.69 μg/ml. Mean steady-state trough concentrations at 12 hours post-dose ranged from 0.12 to 0.19 μg/ml. Mortality due to anthrax for animals that received a 30-day regimen of oral ciprofloxacin
beginning 24 hours post-exposure was significantly lower (1/9), compared to the placebo group (9/10) [p= 0.001]. The one ciprofloxacin-treated animal that died of anthrax did so following the 30-day drug administration period.  

Instructions To The Pharmacist For Use/Handling Of CIPRO Oral Suspension:

CIPRO Oral Suspension is supplied in 5% (5g ciprofloxacin in 100 mL) and 10% (10g ciprofloxacin in 100 mL) strengths. The drug product is composed of two components (microcapsules and diluent) which must be combined prior to dispensing.

One teaspoonful (5 mL) of 5% ciprofloxacin oral suspension = 250 mg of ciprofloxacin.
One teaspoonful (5 mL) of 10% ciprofloxacin oral suspension = 500 mg of ciprofloxacin.

Appropriate Dosing Volumes of the Oral Suspensions:

<table>
<thead>
<tr>
<th>Dose</th>
<th>5%</th>
<th>10%</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 mg</td>
<td>5 mL</td>
<td>2.5 mL</td>
</tr>
<tr>
<td>500 mg</td>
<td>10 mL</td>
<td>5 mL</td>
</tr>
<tr>
<td>750 mg</td>
<td>15 mL</td>
<td>7.5 mL</td>
</tr>
</tbody>
</table>

Preparation of the suspension:

1. The small bottle contains the microcapsules, the large bottle contains the diluent.

2. Open both bottles. Child-proof cap: Press down according to instructions on the cap while turning to the left.

3. Pour the microcapsules completely into the larger bottle of diluent. Do not add water to the suspension.
4. Remove the top layer of the diluent bottle label (to reveal the CIPRO Oral Suspension label). Close the large bottle completely according to the directions on the cap and shake vigorously for about 15 seconds. The suspension is ready for use.

CIPRO Oral Suspension should not be administered through feeding tubes due to its physical characteristics.

Instruct the patient to shake CIPRO Oral Suspension vigorously each time before use for approximately 15 seconds and not to chew the microcapsules.

References:
3. Report presented at the FDA’s Anti-Infective Drug and Dermatological Drug Product’s Advisory Committee meeting, March 31, 1993, Silver Spring MD. Report available from FDA, CDER, Advisors and Consultants Staff, HFD-21, 1901 Chapman Avenue, Room 200, Rockville, MD 20852, USA.
4. 21 CFR 314.510 (Subpart H – Accelerated Approval of New Drugs for Life-Threatening Illnesses).

**PATIENT INFORMATION ABOUT**

**CIPRO® (ciprofloxacin hydrochloride) TABLETS**

**CIPRO® (ciprofloxacin) ORAL SUSPENSION**

This section contains important patient information about CIPRO (ciprofloxacin hydrochloride) Tablets and CIPRO (ciprofloxacin) Oral Suspension and should be read completely before you begin treatment. This section does not take the place of discussion with your doctor or health care professional about your medical condition or your treatment. This section does not list all benefits and risks of CIPRO. If you have any concerns about you condition or your medicine, ask your doctor. Only your doctor can determine if CIPRO is right for you.

**What is CIPRO?**

CIPRO is an antibiotic used to treat bladder, kidney, prostate, cervix, stomach, intestine, lung, sinus, bone, and skin infections caused by certain germs called bacteria. CIPRO kills many types of bacteria that can infect these areas of the body. CIPRO has been shown in a large number of clinical trials to be safe and effective for the treatment of bacterial infections.

Sometimes viruses rather than bacteria may infect the lungs and sinuses (for example the common cold). CIPRO, like all other antibiotics, does not kill viruses. You should contact your doctor if your condition is not improving while taking CIPRO.

**CIPRO Tablets** are white to slightly yellow in color and are available in 100 mg, 250 mg, 500 mg and 750 mg strengths. CIPRO Oral Suspension is white to slightly yellow in color and is available in concentrations of 250 mg per teaspoon (5%) and 500 mg per teaspoon (10%).

**How and when should I take CIPRO?**

**CIPRO Tablets:**

Unless directed otherwise by your physician, CIPRO should be taken twice a day at approximately the same time, in the morning and in the evening. CIPRO can be taken with food or on an empty stomach. CIPRO should not be taken with dairy products (like milk or yogurt) or calcium-fortified juices alone; however, CIPRO may be taken with a meal that contains these products.

You should take CIPRO for as long as your doctor prescribes it, even after you start to feel better. Stopping an antibiotic too early may result in failure to cure your infection. Do not take a double dose of CIPRO even if you miss a dose by mistake.
CIPRO Oral Suspension:

Take CIPRO Oral Suspension in the same way as above. In addition, remember to shake the bottle vigorously each time before use for approximately 15 seconds to make sure the suspension is mixed well. Be sure to swallow the required amount of suspension. Do not chew the microcapsules. Close the bottle completely after use. The product can be used for 14 days when stored in a refrigerator or at room temperature. After treatment has been completed, any remaining suspension should be discarded.

Who should not take CIPRO?

You should not take CIPRO if you have ever had a severe reaction to any of the group of antibiotics known as “quinolones”.

CIPRO is not recommended during pregnancy or nursing, as the effects of CIPRO on the unborn child or nursing infant are unknown. If you are pregnant or plan to become pregnant while taking CIPRO talk to your doctor before taking this medication.

In general, CIPRO is not recommended for persons less than 18 years of age.

What are the possible side effects of CIPRO?

CIPRO is generally well tolerated. The most common side effects, which are usually mild, include nausea, diarrhea, vomiting, and abdominal pain/discomfort. If diarrhea persists, call your health care professional.

Rare cases of allergic reactions have been reported in patients receiving quinolones, including CIPRO, even after just one dose. If you develop hives, difficulty breathing, or other symptoms of a severe allergic reaction, seek emergency treatment right away. If you develop a skin rash, you should stop taking CIPRO and call your health care professional.

Some patients taking quinolone antibiotics may become more sensitive to sunlight or ultraviolet light such as that used in tanning salons. You should avoid excessive exposure to sunlight or ultraviolet light while you are taking CIPRO.

You should be careful about driving or operating machinery until you are sure CIPRO is not causing dizziness. Convulsions have been reported in patients receiving quinolone antibiotics including ciprofloxacin. Be sure to let your physician know if you have a history of convulsions. Quinolones, including ciprofloxacin, have been rarely associated with other central nervous system events including confusion, tremors, hallucinations, and depression.

CIPRO has been rarely associated with inflammation of tendons. If you experience pain, swelling or rupture of a tendon, you should stop taking CIPRO and call your health care professional.

If you notice any side effects not mentioned in this section, or if you have any concerns about side effects you may be experiencing, please inform your health care professional.
What about other medications I am taking?

CIPRO can affect how other medicines work. Tell your doctor about all other prescription and non-prescription medicines or supplements you are taking. This is especially important if you are taking theophylline. Other medications including warfarin, glyburide, and phenytoin may also interact with CIPRO.

Many antacids, multivitamins, and other dietary supplements containing magnesium, calcium, aluminum, iron or zinc can interfere with the absorption of CIPRO and may prevent it from working. Other medications such as sulcrafate and Videx® (didanosine) chewable/buffered tablets or pediatric powder may also stop CIPRO from working. You should take CIPRO either 2 hours before or 6 hours after taking these products.

What if I have been prescribed CIPRO for possible anthrax exposure?

CIPRO has been approved to reduce the chance of developing anthrax infection following exposure to the anthrax bacteria. In general, CIPRO is not recommended for children; however, it is approved for use in patients younger than 18 years old for anthrax exposure. If you are pregnant, or plan to become pregnant while taking CIPRO, you and your doctor should discuss if the benefits of taking CIPRO for anthrax outweigh the risks.

CIPRO is generally well tolerated. Side effects that may occur during treatment to prevent anthrax might be acceptable due to the seriousness of the disease. You and your doctor should discuss the risks of not taking your medicine against the risks of experiencing side effects.

CIPRO can cause dizziness, confusion, or other similar side effects in some people. Therefore, it is important to know how CIPRO affects you before driving a car or performing other activities that require you to be alert and coordinated such as operating machinery.

Your doctor has prescribed CIPRO only for you. Do not give it to other people. Do not use it for a condition for which it was not prescribed. You should take your CIPRO for as long as your doctor prescribes it; stopping CIPRO too early may result in failure to prevent anthrax.

Remember:

Do not give CIPRO to anyone other than the person for whom it was prescribed.

Take your dose of CIPRO in the morning and in the evening.

Complete the course of CIPRO even if you are feeling better.

Keep CIPRO and all medications out of reach of children.

Bayer Corporation
Pharmaceutical Division
400 Morgan Lane
West Haven, CT 06516 USA

Rx Only
CIPRO (ciprofloxacin*) 5% and 10% Oral Suspension Made in Italy. Printed in U.S.A.

* Does not comply with USP with regards to “loss on drying” and “residue on ignition”.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

- ------------------------

Renata Albrecht
4/17/02 05:10:31 PM
APPLICATION NUMBER:

19-537 / S-048, S-050, S-051
20-780 / S-012, S-014, S-015

MEDICAL and CLINICAL
PHARMACOLOGY / BIOPHARMACEUTICS
REVIEW
Medical and Clinical Pharmacology/Biopharmaceutics Review of Supplemental Labeling Revisions (SLRs):

**Sponsor:** Bayer Corporation Pharmaceutical Division

**Products:** CIPRO® (ciprofloxacin) Tablets, 100 mg, 250 mg, 500 mg, 750 mg
CIPRO® (ciprofloxacin) Oral Suspension, 5% and 10%, 250 mg, 500 mg

**Materials Reviewed:**

### NDA 19-537 (Tablets)

<table>
<thead>
<tr>
<th>SLR</th>
<th>Date submitted</th>
<th>Date received</th>
<th>Date completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>048</td>
<td>September 11, 2003</td>
<td>September 15, 2003</td>
<td>March 2, 2004</td>
</tr>
<tr>
<td>050</td>
<td>January 26, 2004</td>
<td>January 27, 2004</td>
<td>March 2, 2004</td>
</tr>
<tr>
<td>051</td>
<td>January 26, 2004</td>
<td>January 28, 2004</td>
<td>March 2, 2004</td>
</tr>
</tbody>
</table>

**Amendments**

<table>
<thead>
<tr>
<th>SLR</th>
<th>Date Submitted</th>
<th>Date Received</th>
<th>Date Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>048</td>
<td>November 7, 2003</td>
<td>November 12, 2003</td>
<td>March 2, 2004</td>
</tr>
<tr>
<td></td>
<td>February 25, 2004</td>
<td>February 27, 2004</td>
<td>March 2, 2004</td>
</tr>
<tr>
<td></td>
<td>March 10, 2004</td>
<td>March 12, 2004</td>
<td>March 15, 2004</td>
</tr>
<tr>
<td>050</td>
<td>February 25, 2004</td>
<td>February 27, 2004</td>
<td>March 2, 2004</td>
</tr>
<tr>
<td></td>
<td>March 10, 2004</td>
<td>March 12, 2004</td>
<td>March 15, 2004</td>
</tr>
<tr>
<td>051</td>
<td>February 25, 2004</td>
<td>February 27, 2004</td>
<td>March 2, 2004</td>
</tr>
<tr>
<td></td>
<td>March 10, 2004</td>
<td>March 12, 2004</td>
<td>March 15, 2004</td>
</tr>
</tbody>
</table>

### NDA 20-780 (Oral Suspension)

<table>
<thead>
<tr>
<th>SLR</th>
<th>Date Submitted</th>
<th>Date Received</th>
<th>Date Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>012</td>
<td>September 11, 2003</td>
<td>September 15, 2003</td>
<td>March 2, 2004</td>
</tr>
<tr>
<td>014</td>
<td>January 26, 2004</td>
<td>January 27, 2004</td>
<td>March 2, 2004</td>
</tr>
<tr>
<td>015</td>
<td>January 26, 2004</td>
<td>January 28, 2004</td>
<td>March 2, 2004</td>
</tr>
</tbody>
</table>

**Amendments**

<table>
<thead>
<tr>
<th>SLR</th>
<th>Date Submitted</th>
<th>Date Received</th>
<th>Date Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>012</td>
<td>February 25, 2004</td>
<td>February 27, 2004</td>
<td>March 2, 2004</td>
</tr>
<tr>
<td></td>
<td>March 10, 2004</td>
<td>March 12, 2004</td>
<td>March 15, 2004</td>
</tr>
<tr>
<td>014</td>
<td>February 25, 2004</td>
<td>February 27, 2004</td>
<td>March 2, 2004</td>
</tr>
<tr>
<td></td>
<td>March 10, 2004</td>
<td>March 12, 2004</td>
<td>March 15, 2004</td>
</tr>
<tr>
<td>015</td>
<td>February 25, 2004</td>
<td>February 27, 2004</td>
<td>March 2, 2004</td>
</tr>
<tr>
<td></td>
<td>March 10, 2004</td>
<td>March 12, 2004</td>
<td>March 15, 2004</td>
</tr>
</tbody>
</table>


**Background:** Ciprofloxacin (CIPRO®) is a fluoroquinolone antibacterial agent. NDA 19-537 (tablet) was originally approved on October 22, 1987. NDA 20-780 (oral suspension) was originally approved on September 26, 1997. The tablet and oral suspension have shared one label since that time. The most recent labeling approval for these NDAs occurred on April 17, 2002. No other labeling changes have been approved since that date.
NDA 19-537/S-048, S-050, S-051
NDA 20-780/S-012, S-014, S-015

**NDA 19-537/S-048 (tablets) and NDA 20-780/S-012 (oral solution):**
Supplement 012 and 048 were submitted as Changes Being Effected (CBE) and provide for additional safety information in the label. Revisions are included in the WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE sections of the package insert.

**NDA 19-537/SLR-050 (tablets) and NDA 20-780/SLR-014 (oral solution):**
Supplements 050 and 014 were submitted as Changes Being Effected (CBE) and provide for antibacterial drug resistance labeling revisions as specified in the Division’s September 11, 2003 letter. This CBE request letter was sent per the Final Rule entitled “Labeling Requirements for Systemic Antibacterial Drug Products Intended for Human Use “(68FR 6062, February 6, 2003).

**NDA 19-537/SLR-051 (tablets) and NDA 20-780/SLR-015 (oral solution):**
Supplements 051 and 014 were submitted as Changes Being Effected (CBE) and provide for additional safety information in the label. Revisions are included in the WARNINGS, and ADVERSE REACTIONS sections of the package insert.

**Electronic Labeling Comparison:**
The approved CIPRO package insert dated April 17, 2002 was electronically compared to the proposed draft package insert dated March 10, 2004. The changes were as follows:

- **Double underline**=added text
- **Strikeout**=deleted text

**NDA 19-537/S-048 (tablets)**
**NDA 20-780/S-012 (oral solution)**

1. **WARNINGS**

Achilles and other tendon ruptures that required surgical repair or resulted in prolonged disability have been reported with ciprofloxacin and other quinolones. Post-marketing surveillance reports indicate that the risk may be increased in patients receiving concomitant corticosteroids, especially in the elderly. Ciprofloxacin should be discontinued if the patient experiences pain, inflammation, or rupture of a tendon.

2. **PRECAUTIONS, Drug Interactions:**

Quinolones, including ciprofloxacin, have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives. When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be closely monitored.

Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in the serum. This should be considered if patients are receiving both drugs concomitantly.
Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin potentially leading to increased plasma levels of methotrexate. This might increase the risk of methotrexate associated toxic reactions. Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.

Metoclopramide significantly accelerates the absorption of oral ciprofloxacin resulting in a shorter time to reach maximum plasma concentrations. No significant effect was observed on the bioavailability of ciprofloxacin.

Animal studies have shown that the combination of very high doses of quinolones and certain non-steroidal anti-inflammatory agents (but not acetylsalicylic acid) can provoke convulsions.

BODY AS A WHOLE: headache, abdominal pain/discomfort, foot pain, pain, pain in extremities, injection site reaction (ciprofloxacin intravenous)

CARDIOVASCULAR: palpitation, atrial flutter, ventricular ectopy, syncope, hypertension, angina pectoris, myocardial infarction, cardiopulmonary arrest, cerebral thrombosis, phlebitis, tachycardia, migraine, hypotension

CENTRAL NERVOUS SYSTEM: restlessness, dizziness, lightheadedness, insomnia, nightmares, hallucinations, manic reaction, irritability, tremor, ataxia, convulsive seizures, lethargy, drowsiness, weakness, malaise, anorexia, phobia, depersonalization, depression, paresthesia, abnormal gait, grand mal convolution (See above.) (See PRECAUTIONS.)

GASTROINTESTINAL: painful oral mucosa, oral candidiasis, dysphagia, intestinal perforation, gastrointestinal bleeding (See above.) Cholestatic jaundice, hepatitis jaundice has been reported.

HEMIC/LYMPHATIC: lymphadenopathy, petechia
METABOLIC/NUTRITIONAL: amylase increase, lipase increase
MUSCULOSKELETAL: arthralgia or back pain, joint stiffness, achiness, neck or chest pain, flare up of gout
RENAL/UREGENITAL: interstitial nephritis, nephritis, renal failure, polyuria, urinary retention, urethral bleeding, vaginitis, acidosis, breast pain
RESPIRATORY: dyspnea, epistaxis, laryngeal or pulmonary edema, hiccough, hemoptyisis, bronchospasm, pulmonary embolism
SKIN/HYPERSENSITIVITY: pruritus, urticaria, photosensitivity, flushing, fever, chills, angioedema, edema of the face, neck, lips, conjunctivae or hands, cutaneous candidiasis, hyperpigmentation, erythema, nodosum, sweating
Allergic reactions ranging from urticaria to anaphylactic reactions have been reported. (See WARNINGS.)
SPECIAL SENSES: blurred vision, disturbed vision (change in color perception, overbrightness of lights), decreased visual acuity, diplopia, eye pain, tinnitus, hearing loss, bad taste, chromatopsia

Post-Marketing Adverse Events: Additional adverse events, regardless of relationship to drug. The following adverse events have been reported from worldwide marketing experience with quinolones, including ciprofloxacin are: ciprofloxacin. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these events in labeling are typically based on one or more of the following factors: (1) seriousness of the event, (2) frequency of the reporting, or (3) strength of causal connection to the drug.
Agitation, agranulocytosis, albuminuria, anaphylactic reactions, anosmia, candiduria, cholesterol elevation (serum), confusion, constipation, delirium, dyspepsia, dysphagia, erythema multiforme, exfoliative dermatitis, fixed eruption, flatulence, glucose elevation (blood), hemolytic anemia, hepatic failure, hepatic necrosis, hyperesthesia, hypotonia, hypothermia, hypotension (postural), jaundice, marrow depression (life threatening), methemoglobinemia, monolossis (oral, gastrointestinal, vaginal) myalgia, myasthenia, myasthenia gravis (possible exacerbation), myelosus, myasthenus, pancreatitis, panmyositis, pancytopenia (life threatening or fatal outcome), polymyositis alteration (serum), potassium elevation (serum), prothrombin time prolongation or decrease, pseudomembranous colitis (The onset of pseudomembranous colitis symptoms may occur during or after antimicrobial treatment.), psychotic (toxic), renal calculi, serum sickness like reaction, Stevens-Johnson syndrome, taste loss, tendinitis, tendon rupture, toxic epidermal necrolysis, triglyceride elevation (serum), twitching, vaginal candidiasis, and vasculitis. (See PRECAUTIONS.)

4. OVERDOSAGE
In the event of acute overdosage, reversible renal toxicity has been reported in some cases. The stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be carefully observed and given supportive treatment, including monitoring of renal function and administration of magnesium, aluminum or calcium containing antacids which can treatment—reduce the absorption of ciprofloxacin. Adequate hydration must be
maintained. Only a small amount of ciprofloxacin (< 10%) is removed from the body after hemodialysis or peritoneal dialysis. Single doses of ciprofloxacin were relatively non-toxic via the oral route of administration in mice, rats, and dogs. No deaths occurred within a 14-day post treatment observation period at the highest oral doses tested; up to 5000 mg/kg in either rodent species, or up to 2500 mg/kg in the dog. Clinical signs observed included hypoactivity and cyanosis in both rodent species and severe vomiting in dogs. In rabbits, significant mortality was seen at doses of ciprofloxacin > 2500 mg/kg. Mortality was delayed in these animals, occurring 10-14 days after dosing.

In mice, rats, rabbits and dogs, significant toxicity including tonic/clonic convulsions was observed at intravenous doses of ciprofloxacin between 125 and 300 mg/kg.

The changes to the PRECAUTIONS, Drug Interactions section are based upon a published article discussing two case reports where a possible interaction between methotrexate may have occurred, a pharmacokinetic study conducted by Bayer evaluating the effect of metoclopramide on gastric absorption of ciprofloxacin, and pre-clinical data on the potential for quinolones to cause convulsion when used with NSAIDs.

The changes to the OVERDOSAGE section provide clinicians with information on how to manage acute overdosage. It is known that administration of magnesium and calcium containing antacids reduces the absorption of ciprofloxacin and this is information is currently in the drug-interactions section of the label. It is possible to make use of this interaction to reduce absorption of ciprofloxacin in cases of acute overdose.

These changes were found to be acceptable by Dr. Meyer, Dr. Chilukuri, and Dr. Hundley.

NDA 19-537/SLR-050 (tablets)
NDA 20-780/SLR-014 (oral solution)

1. The following sentence was added at the beginning of the label under the Product Name:

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRO Tablets and CIPRO Oral Suspension and other antibacterial drugs, CIPRO Tablets and CIPRO Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

2. The following was added as the last paragraph in the INDICATIONS AND USAGE section:

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRO Tablets and CIPRO Oral Suspension and other antibacterial drugs, CIPRO Tablets and CIPRO Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empirical selection of therapy.
3. The following was added as the last paragraph in the PRECAUTIONS section, General: subsection:

Prescribing CIPRO Tablets and CIPRO Oral Suspension in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

4. The following was added as the first bullet in the PRECAUTIONS section, Information for Patients: subsection:

- that antibacterial drugs including CIPRO Tablets and CIPRO Oral Suspension should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When CIPRO Tablets and CIPRO Oral Suspension is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by CIPRO Tablets and CIPRO Oral Suspension or other antibacterial drugs in the future.

The proposed labeling changes submitted by the company are identical to those listed in our CBE request letter and respond to the Final Rule entitled “Labeling Requirements for Systemic Antibacterial Drug Products Intended for Human Use “(68FR 6062, February 6, 2003).

NDA 19-537/ SLR-051 (tablets)
NDA 20-780/ SLR-015 (oral solution)

1. The following text was added to the eighth paragraph of the WARNINGS section:

After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against C. difficile colitis. Drugs that inhibit peristalsis should be avoided.

2. ADVERSE REACTIONS

SKIN/HYPERSENSITIVITY: allergic reaction, pruritus, urticaria, photosensitivity, flushing, fever, chills, angioedema, edema of the face, neck, lips, conjunctivae or hands, cutaneous candidiasis, hyperpigmentation, erythema nodosum, sweating
The changes to the WARNINGS and ADVERSE REACTIONS are warranted based upon post-marketing surveillance reports. The additional wording regarding avoidance of drugs that inhibit peristalsis is based upon standard clinical management of patients with C. difficile colitis. These changes were found to be acceptable by Dr. Meyer and Dr. Chilukuri.

Christine Lincoln RN, MS, MBA
Labeling Reviewer

Joette Meyer, Pharm.D. 3/15/04
Clinical Reviewer

Dakshina Chilukuri, Ph.D. 3/5/04
Clinical Pharmacology/Biopharmaceutics Reviewer

Concurrence:
HFD-590Acting DivDir/R. Albrecht 3/15/04
HFD-590/BiopharmTL/P. Colangelo 3/5/04
HFD-590/Pharm-Tox/Reviewer/ S. Hundley 3/15/04
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
-----------------------------------
Christine Lincoln
3/18/04 09:51:56 PM
INTERDISCIPLINARY

Renata Albrecht
3/23/04 05:22:14 AM
MEDICAL OFFICER
These reviews were final and signed (paper version) on 3/15/2004, the delay in entry into DFS and signing off in DFS is related to the ongoing problems with DFS in the past week